Results 31 to 40 of about 2,820 (114)

Machine Learning Applied to Patient‐Reported Outcomes to Classify Physician‐Derived Measures of Rheumatoid Arthritis Disease Activity

ACR Open Rheumatology, 2022
Objective Patient‐reported outcome (PRO) data have assumed increasing importance in the care of patients with rheumatoid arthritis (RA), yet physician‐derived disease activity measures, such as Clinical Disease Activity Index (CDAI), remain the most ...
Jeffrey R. Curtis, Yujie Su, Shawn Black, Stephen Xu, Wayne Langholff, Clifton O. Bingham, Shelly Kafka, Fenglong Xie   +7 more
doaj   +1 more source

Fever During Anti-integrin Therapy: New Immunodeficiency

European Journal of Case Reports in Internal Medicine, 2020
Background: The causes of inflammatory bowel disease (IBD) have not yet been clearly elucidated, but it is known that genetic susceptibility, altered gut microbiota and environmental factors are all involved, and that a combination of these factors ...
Eleonora Bonfanti, Christian Bracco, Paolo Biancheri, Andrea Falcetta, Marco Badinella Martini, Remo Melchio   +5 more
doaj   +1 more source

Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study [PDF]

The Journal of Rheumatology, 2019
J Rheumatol 2019; doi: 10.3899/jrheum.180718 Recently, the sponsor became aware of data errors related to Bath Ankylosing Spondylitis Metrology Index (BASMI) and the University of California San Francisco (UCSF) Enthesitis Index.
John D, Reveille, Atul, Deodhar, Paul H, Caldron, Anna, Dudek, Diane D, Harrison, Lilianne, Kim, Kim Hung, Lo, Jocelyn H, Leu, Elizabeth C, Hsia   +8 more
openaire   +2 more sources

Maintenance of Efficacy and Safety with Subcutaneous Golimumab Among Patients with Active Rheumatoid Arthritis Who Previously Received Intravenous Golimumab

The Journal of Rheumatology, 2011
Objective.To evaluate the efficacy/safety of subcutaneous (SC) golimumab in patients with rheumatoid arthritis (RA) who previously received intravenous (IV) golimumab with or without methotrexate (MTX).Methods.Adult patients with RA (n = 643) with persistent disease despite MTX (≥ 15 mg/wk for ≥ 3 months) were randomized to IV placebo + MTX (n = 129 ...
Taylor, P, Ritchlin, C, Mendelsohn, A, Baker, D, Kim, L, Xu, Z, Mack, M, Kremer, J   +7 more
openaire   +3 more sources

FRI0486 Intravenous golimumab in adult patients with active psoriatic arthritis: efficacy and safety through week 24 [PDF]

Annals of the Rheumatic Diseases, 2017
Objectives The GO-VIBRANT study was designed to evaluate the safety and efficacy of intravenous (IV) golimumab (GLM) in adult patients (pts) with active PsA (biologic-naive). Methods GO-VIBRANT is a Phase 3, multicenter, randomized, double-blind, placebo (PBO)-controlled trial.
A Kavanaugh, ME Husni, DD Harrison, L Kim, KH Lo, EC Hsia   +5 more
openaire   +1 more source

Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study [PDF]

The Journal of Rheumatology, 2017
Objective. To evaluate the safety and efficacy of intravenous golimumab (GOL) in patients with active ankylosing spondylitis (AS). Methods. In a phase III, randomized, double-blind, placebo (PBO)-controlled trial, 208 patients were ...
Atul, Deodhar, John D, Reveille, Diane D, Harrison, Lilianne, Kim, Kim Hung, Lo, Jocelyn H, Leu, Elizabeth C, Hsia   +6 more
openaire   +2 more sources

Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial [PDF]

Value in Health, 2020
Evaluate the effect of intravenous golimumab on health-related quality of life (HRQoL) in patients with ankylosing spondylitis (AS) through week 28 of the phase III, multicenter, randomized, double-blind, placebo-controlled GO-ALIVE study.Adult patients (n = 208) were randomized to IV golimumab 2 mg/kg (n = 105) at weeks 0, 4, and 12 and every 8 weeks ...
John D, Reveille, Atul, Deodhar, Akgun, Ince, Eric K H, Chan, Steven, Peterson, Nan, Li, Elizabeth C, Hsia, Lilianne, Kim, Kim Hung, Lo, Stephen, Xu, Diane D, Harrison, Chenglong, Han   +11 more
openaire   +2 more sources

THU0348 Safety and efficacy of intravenous golimumab in adult patients with active ankylosing spondylitis: results through week 28 [PDF]

Annals of the Rheumatic Diseases, 2017
Objectives Subcutaneous (SC) golimumab (GLM) is currently approved for adult patients (pts) with RA, PsA, and AS. The GO-ALIVE study was designed to evaluate the safety and efficacy of IV GLM in adult pts with active AS. Methods GO-ALIVE is a Phase 3, multicenter, randomized, double-blind, placebo (PBO)-controlled trial.
A Deodhar, JD Reveille, DD Harrison, L Kim, KH Lo, E Hsia   +5 more
openaire   +1 more source

Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective

Cost Effectiveness and Resource Allocation, 2018
Objective To study cost-effectiveness of an interleukin (IL)-17A inhibitor secukinumab, with other biologics and apremilast in patients with Psoriatic arthritis (PsA) from payer perspective in Finland. Methods In this semi-Markov model, subcutaneous (SC)
Timo Purmonen, Kari Puolakka, Devarshi Bhattacharyya, Minal Jain, Janne Martikainen   +4 more
doaj   +1 more source

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source